Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the prognostic impact of intraoperative cytology results according to tumor sidedness in stage II/III resectable colorectal cancer.

International journal of colorectal disease·2026
Same author

Impact of the number of colorectal cancer lymph node metastases on intraperitoneal lavage cytology: a multi-institutional, prospective, observational study.

Surgery today·2026
Same author

Preoperative carbohydrate antigen 19-9 as a prognostic biomarker in colorectal cancer with synchronous peritoneal metastasis: multicentre cohort study.

BJS open·2026
Same author

Prognostic Power of Ensemble Learning in Colorectal Cancer with Peritoneal Metastasis: A Multi-Institutional Analysis.

Bioengineering (Basel, Switzerland)·2026
Same author

Trends in net survival for patients with brain tumors in Japan, 2000-14 (CONCORD-3).

Japanese journal of clinical oncology·2026
Same author

Trends in net survival of patients with cutaneous melanoma in Japan, 2000-14 (CONCORD-3).

Japanese journal of clinical oncology·2026

Related Experiment Video

Updated: May 2, 2026

Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 15, 2008

28.5K

[Chemotherapy].

Shin Fujita1, Kenjiro Kotake1

  • 1Tochigi Cancer Center.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 7, 2014
PubMed
Summary

Colorectal cancer chemotherapy offers improved survival with toxic regimens like FOLFOX. Treatment personalization and adjuvant chemotherapy for stage III patients are crucial for better outcomes.

Area of Science:

  • Oncology
  • Gastrointestinal Oncology

Context:

  • Colorectal cancer (CRC) treatment has advanced, improving survival rates.
  • Effective chemotherapy regimens (e.g., FOLFOX, CapeOX, FOLFIRI) and targeted therapies (bevacizumab, cetuximab, panitumumab) are available.
  • Regorafenib serves as a third- or fourth-line treatment option for advanced CRC.

Purpose:

  • To outline current chemotherapy strategies for colorectal cancer.
  • To emphasize personalized treatment approaches based on tumor characteristics and patient condition.
  • To discuss the role of conversion and adjuvant chemotherapy in CRC management.

Summary:

  • Current CRC chemotherapy includes FOLFOX, CapeOX, FOLFIRI, and FOLFOXIRI, often combined with targeted agents.
  • Treatment selection should be individualized, considering tumor biology and patient factors.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.8K

Related Experiment Videos

Last Updated: May 2, 2026

Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 15, 2008

28.5K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.8K
  • Conversion therapy (e.g., FOLFOX with cetuximab) and adjuvant chemotherapy (5FU+LV, capecitabine, FOLFOX, CapeOX, S-1) are key for stage III CRC.
  • Oxaliplatin-containing regimens are recommended for high-risk stage III patients despite toxicity.

    • Impact:

    • Improved survival rates for colorectal cancer patients.
    • Tailored treatment strategies enhance therapeutic efficacy and patient outcomes.
    • Adjuvant chemotherapy significantly benefits stage III CRC patients, particularly those at high risk.